Loading stock data…
$85.27-1.12 (-1.30%)
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Edwards Lifesciences Corporation in the Healthcare sector is trading at $85.27 with a market capitalization of $52.8B. Wall Street consensus targets $101.96 (26 analysts), implying a +19.6% move over the next 12 months. The stock is currently 11% below its 52-week high of $96.29, remaining 0.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.74B↑ | $1.65B↑ | $1.57B↑ | $1.55B↑ | $1.53B |
| Gross Profit | $1.35B↑ | $1.29B↑ | $1.23B↑ | $1.21B↑ | $1.19B |
| Operating Income | $519.50M↑ | $514.70M↑ | $370.30M↓ | $425.10M↓ | $430.90M |
| Net Income | $241.90M↓ | $380.70M↑ | $91.20M↓ | $291.10M↓ | $333.20M |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Academic risk and quality models computed from EW's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
GARCH(1,1) 30-day annualised forecast, above the current 24.6% reading.
Fama-French 5-factor market beta. The five factors explain 15% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.